Magazine Article | February 1, 2019

Why Patent Protection Is Key To Commercializing Repurposed Drugs

Source: Life Science Leader

By John Conour

If you’ve been involved in any aspect of drug development in your career, it’s likely you are aware that, on average, only 1 in 10 therapeutic candidates that enter Phase 1 clinical trials is approved. Consequently, the industry is littered with abandoned, shelved drugs, or drugs simply listed as “failures.”